OLMA Valuation

Olema Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

8.350

+0.16(1.954%)1D

OLMA Relative Valuation

OLMA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, OLMA is overvalued; if below, it's undervalued.

Historical Valuation

Olema Pharmaceuticals Inc (OLMA) is now in the Fair zone, suggesting that its current forward PS ratio of 8.35 is considered Fairly compared with the five-year average of -6.88. The fair price of Olema Pharmaceuticals Inc (OLMA) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：8.35

Fair

-3.84

Trailing

Forward

-1.28

EV/EBITDA

Olema Pharmaceuticals Inc. (OLMA) has a current EV/EBITDA of -1.28. The 5-year average EV/EBITDA is -3.74. The thresholds are as follows: Strongly Undervalued below -17.64, Undervalued between -17.64 and -10.69, Fairly Valued between 3.20 and -10.69, Overvalued between 3.20 and 10.15, and Strongly Overvalued above 10.15. The current Forward EV/EBITDA of -1.28 falls within the Historic Trend Line -Fairly Valued range.

-1.15

EV/EBIT

Olema Pharmaceuticals Inc. (OLMA) has a current EV/EBIT of -1.15. The 5-year average EV/EBIT is -4.17. The thresholds are as follows: Strongly Undervalued below -19.34, Undervalued between -19.34 and -11.76, Fairly Valued between 3.41 and -11.76, Overvalued between 3.41 and 11.00, and Strongly Overvalued above 11.00. The current Forward EV/EBIT of -1.15 falls within the Historic Trend Line -Fairly Valued range.

8.35

Olema Pharmaceuticals Inc. (OLMA) has a current PS of 8.35. The 5-year average PS is 0.07. The thresholds are as follows: Strongly Undervalued below -1.45, Undervalued between -1.45 and -0.69, Fairly Valued between 0.83 and -0.69, Overvalued between 0.83 and 1.59, and Strongly Overvalued above 1.59. The current Forward PS of 8.35 falls within the Strongly Overvalued range.

-3.94

P/OCF

Olema Pharmaceuticals Inc. (OLMA) has a current P/OCF of -3.94. The 5-year average P/OCF is -8.42. The thresholds are as follows: Strongly Undervalued below -25.93, Undervalued between -25.93 and -17.17, Fairly Valued between 0.33 and -17.17, Overvalued between 0.33 and 9.09, and Strongly Overvalued above 9.09. The current Forward P/OCF of -3.94 falls within the Historic Trend Line -Fairly Valued range.

-3.32

P/FCF

Olema Pharmaceuticals Inc. (OLMA) has a current P/FCF of -3.32. The 5-year average P/FCF is -7.19. The thresholds are as follows: Strongly Undervalued below -21.25, Undervalued between -21.25 and -14.22, Fairly Valued between -0.16 and -14.22, Overvalued between -0.16 and 6.87, and Strongly Overvalued above 6.87. The current Forward P/FCF of -3.32 falls within the Historic Trend Line -Fairly Valued range.

Olema Pharmaceuticals Inc (OLMA) has a current Price-to-Book (P/B) ratio of 1.66. Compared to its 3-year average P/B ratio of 1.94 , the current P/B ratio is approximately -14.46% higher. Relative to its 5-year average P/B ratio of 1.89, the current P/B ratio is about -12.06% higher. Olema Pharmaceuticals Inc (OLMA) has a Forward Free Cash Flow (FCF) yield of approximately -0.22%. Compared to its 3-year average FCF yield of -27.20%, the current FCF yield is approximately -99.18% lower. Relative to its 5-year average FCF yield of -24.54% , the current FCF yield is about -99.10% lower.

1.66

P/B

Median3y

1.94

Median5y

1.89

-0.22

FCF Yield

Median3y

-27.20

Median5y

-24.54

Competitors Valuation Multiple

The average P/S ratio for OLMA's competitors is 6.92, providing a benchmark for relative valuation. Olema Pharmaceuticals Inc Corp (OLMA) exhibits a P/S ratio of 8.35, which is 20.58% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

OLMA.O

Olema Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

7.60

567.58M

SIGA.O

SIGA Technologies Inc

Compass Therapeutics Inc.

4.23

752.36M

CTMX.O

CytomX Therapeutics Inc

Performance Decomposition

Market capitalization of OLMA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of OLMA in the past 1 year is driven by Unknown.